Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.
Shield Therapeutics is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer®
Find out moreFeraccru®/Accrufer® is a novel oral product that addresses the needs of patients who cannot tolerate existing oral iron products and offers a clear alternative to IV iron therapy.
Find out moreThe content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.
RT @ruth_proactive: $STX Shield Therapeutics takes bold approach in the US https://t.co/iqkGIh9xNe @shieldTx $1JS #STX #1JS
A great new addition to our team. Greg Madison welcomes Jose A Menoyo MD as our new Chief Medical Officer. Read mo… https://t.co/UFPbJGWkcn
RT @VOXmarkets: Shield Therapeutics - Jose A. Menoyo Appointed as Chief Medical Officer #STX @ShieldTx https://t.co/WBsmVEBcE0 #voxmarkets…
